Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
Older
Dec 20, 2023
Completion of enrolment in Neuren's Angelman P2 trial
Dec 19, 2023
Application for quotation of securities - NEU
Dec 18, 2023
Investor presentation, 18 December 2023
Dec 18, 2023
P2 trial shows significant improvements in Phelan-McDermid
Dec 14, 2023
Trading Halt
Dec 05, 2023
Neuren completes enrolment in Pitt Hopkins Phase 2 trial
Nov 20, 2023
Comment on media speculation
Nov 13, 2023
Neuren completes Phelan-McDermid syndrome Phase 2 trial
Nov 08, 2023
Investor presentation, 8 November 2023
Nov 03, 2023
DAYBUE net sales US$66.9 million in Q3 2023
1
2
3
4
5
Next
